Preclinical studies have demonstrated that intraperitoneal administration of monosodium glutamate (MSG) reduces PSMA ligand retention in the salivary glands and kidneys without considerably affecting tumor uptake [153]. This evidence concerns the gene FOLH1 and neoplasm.